Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Accelerate Diagnostics (GB:0H8E)
LSE:0H8E
RESEARCH TOOLSreports
Holding GB:0H8E?
Track your performance easily
0H8E Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.85 - $6.84
Previous Close$1.59
Volume245.00
Average Volume (3M)539.00
Market Cap
$40.02M
Enterprise Value$72.68M
Total Cash (Recent Filing)$9.75M
Total Debt (Recent Filing)$42.41M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Nov 07, 2024EPS Estimate
-$0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.07
Shares Outstanding23,679,383
10 Day Avg. Volume25
30 Day Avg. Volume539
Standard Deviation0.27
R-Squared0.00113
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)-0.75
Price to Sales (P/S)2.96
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.94
Enterprise Value/Gross Profit28.50
Enterprise Value/Ebitda-2.30
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Accelerate Diagnostics News
PremiumCompany Announcements
Accelerate Diagnostics Unveils Executive Incentive Plan Linked to FDA Goals
PremiumCompany Announcements
Accelerate Diagnostics’ Shareholder Decisions at Annual Meeting
Options Prices
Currently, No data available
---
Ownership Overview
44.09% Insiders
1.94% Mutual Funds
15.90% Other Institutional Investors
38.07% Public Companies and
Individual Investors
0H8E FAQ
What was Accelerate Diagnostics’s price range in the past 12 months?
Accelerate Diagnostics lowest share price was $0.85 and its highest was $6.84 in the past 12 months.
What is Accelerate Diagnostics’s market cap?
Currently, no data Available
When is Accelerate Diagnostics’s upcoming earnings report date?
Accelerate Diagnostics’s upcoming earnings report date is Nov 07, 2024 which is in 42 days.
How were Accelerate Diagnostics’s earnings last quarter?
Accelerate Diagnostics released its earnings results on Aug 08, 2024. The company reported -$0.458 earnings per share for the quarter, beating the consensus estimate of -$0.551 by $0.093.
Is Accelerate Diagnostics overvalued?
According to Wall Street analysts Accelerate Diagnostics’s price is currently Overvalued.
Does Accelerate Diagnostics pay dividends?
Accelerate Diagnostics does not currently pay dividends.
What is Accelerate Diagnostics’s EPS estimate?
Accelerate Diagnostics’s EPS estimate is -$0.47.
How many shares outstanding does Accelerate Diagnostics have?
Accelerate Diagnostics has 23,679,382 shares outstanding.
What happened to Accelerate Diagnostics’s price movement after its last earnings report?
Accelerate Diagnostics reported an EPS of -$0.458 in its last earnings report, beating expectations of -$0.551. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Accelerate Diagnostics?
Among the largest hedge funds holding Accelerate Diagnostics’s share is Oracle Investment Management Inc. It holds Accelerate Diagnostics’s shares valued at N/A.
---
Accelerate Diagnostics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-68.47%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-54.15%
Trailing 12-Months
Company Description
Accelerate Diagnostics
Accelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. Its products include Accelerate Pheno and Accelerate PhenoTest. The company was founded on May 26, 1982 and is headquartered in Tucson, AZ.
---
0H8E Earnings Call
Q2 2024
0:00 / 0:00
---
0H8E Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---